

International School of Stinical Oncology



Personomic Compass

April 10th-11th, 2025

Scientific Book

Orchestrated by



Perfect Touch Events

Endorsed by

ASCO

AMERICAN SOCIETY OF CLINICAL ONCOLOGY KNOWLEDGE CONQUERS CANCER

Marriott.

CAIRO HOTEL &
OMAR KHAYYAM CASINO

www.isco-eg.org






Prof. Khaled Abdel Ghaffar

Minister of Health & Population













DÉPARTEMENT DE MÉDECINE ONCOLOGIQUE
CHEF DE DÉPARTEMENT
PROFESSEUR LAURENCE ALBIGES

CHEF DE DÉPARTEMENT ADJOINT DOCTEUR A. LEARY

SECRÉTARIAT

L. CHEROT

Tél. : 33 (0) 1 42 11 43 17 laury.cherot@gustaveroussy.fr A. PEYCLIET

Tél. : 33 (0) 1 42 11 43 39 audrey.peycliet@gustaveroussy.fr

Fax: 33 (0)1 42 11 52 11

Villejuif, February 27th, 2025

MÉDECINS

DR P. ABDAYEM

DR M. ADI-MOKDAD

PR L. ALBIGÈS

PR F. ANDRÉ

DR Z. AP THOMAS

DR M. AUPOMEROL

DR D. BELKADI-SADOU

DR H. BELKHODJA

DR G. BERAUD-CHAULET

DR A. BERNARD-TESSIER

PR B. BESSE

DR V. BOIGE

DR A. BOILEVE

DR C. BOUTROS

DR O. CARON

DR O. CARON DR B. CHEAIR DRIS, COSCONEA DR S. DELALOGE PR M. DUCREUX DR S. DUMONT DR F FI RASSY PR K. FIZAZI DR R. FLIPPOT DR M. FRELAUT DR A. FUEREA DR A. GAZZAH DR V. GOLDBARG DR D. GUYON DR C. HENON DR A. HOLLEBECQUE DR P. LAVAUD

DR C. LAZAROVICI-NAGERA

DR J. MICHELS
DR N. NAOUN
DR C. PARISI
DR A. PATRIKIDOU
DR P. PAUTIER
DR B. PISTILLI
PR D. PLANCHARD
DR C. POISSON
DR T. PUDLARZ
DR J. REMON MASIP
DR J. RIBEIRO

PR C. ROBERT DR E. ROUTIER DR M. SAKKAL DR C. SMOLENSCHI

DR A. LE CESNE DR A. LEARY

DR Y. LORIOT

DR M. VALERY
DR I. VAZ-DUARTE-LUIS
DR L. VERON
DR B. VERRET
DR A. VIANSONE
DR D. WEHRER

Dear Prof Emad Barsoum, Dear Prof El-Nahas, Dear Prof Arafat, Dear Prof Yassin,

Many thanks for your proposition to Gustave Roussy to endorse the Scientific program of the 2025 ISCO Annual Congress.

On behalf of Gustave Roussy and as Head of the International Academic Affairs, I am happy to confirm that Gustave Roussy will endorse the Scientific program of the 2025 ISCO Annual Congress.

Gustave Roussy will also be happy to welcome the Young Oncologists who will win the scientific contest of the meeting for a one month observership program by the third-fourth quarter of 2025.

All my best Wishes for this great event!

Sincerely yours.

Prof Karim Fizazi MD, PhD

Professeur Karim FIZAZI
Profes



CHAIR OF THE BOARD

Lynn M. Schuchter, MD, FASCO

PRESIDENT

Robin T. Zon, MD, FACP, FASCO

PRESIDENT-ELECT

Eric J. Small, MD, FASCO

PAST PRESIDENT

Eric P. Winer, MD, FASCO

TREASURER

Taofeek K. Owonikoko, MD, PhD, FASCO

TREASURER-ELECT

Carolyn B. Hendricks, MD, FASCO

DIRECTORS

Fredrick Chite Asirwa, MD, MBChB

Mariana Chavez Mac Gregor, MD,

MSc, FASCO

Toni K. Choueiri, MD, FASCO

Jhanelle E. Gray, MD

Clarissa Mathias, MD, PhD, FASCO

Kathleen N. Moore, MD, MS

Ann H. Partridge, MD, MPH, FASCO

Debra A. Patt, MD, PhD, MBA, FASCO

Gladys I. Rodriguez, MD, FASCO

Abby R. Rosenberg, MD, MS,

MA, FAAP

Jennifer S. Temel, MD, FASCO

Karen M. Winkfield, MD, PhD, FASCO

EX-OFFICIO MEMBERS

CHAIR, CONQUER CANCER BOARD Howard A. Burris III, MD,

FACP, FASCO

CHIEF EXECUTIVE OFFICER

Clifford A. Hudis, MD, FACP, FASCO October 14, 2024

Dr. Elabrar Ebrahim Elmasry International School of Clinical Oncology (ISCO) ebrar.ebrahim@isco-eg.org

Dear Dr. Elmasry:

I am pleased to report that the IAC Steering Committee has approved the application submitted for endorsement by the International School of Clinical Oncology (ISCO) on behalf of the "Personomic Compass," which will be held April 10-11, 2025, in Cairo, Egypt.

No funding has been granted for this meeting. ASCO will provide the ASCO logo and include the event on ASCO event calendars. If ASCO can assist in providing materials for the meeting, such as slides or background materials, we are happy to do so.

We ask that you work with the ASCO Center for Global Impact to coordinate these details. Please note that the ASCO national office must review and approve any materials bearing the ASCO logo prior to printing, and that ASCO cannot provide continuing education credits for the course.

Requirements to be followed by the event organizers for an ASCO Endorsement include the following:

- 1. Endorsement implies that ASCO has approved in an official capacity the educational program and has participated in its development. For this program, materials will be created by the speakers.
- 2. All materials bearing the ASCO name must be pre-approved by ASCO in writing.
- 3. Explicit and clear learning objectives must be developed for the educational program of the event and listed in the program brochure. Major changes to the program or educational activities must be forwarded to the ASCO Center for Global Impact for review and approval.
- 4. During the planning of the conference, ASCO must be provided with copies of communications to any speakers who have been solicited through ASCO and with promotional materials for the conference. This will assist in the promotion of the conference through ASCO channels. There will be an ASCO-

appointed member on the planning committee.



Welcome to the "ISCO" the International School of Clinical Oncology annual congress, where a diverse community of oncology professionals gathers for an unforgettable experience.


Prepare to immerse yourself in an extraordinary gathering of leading experts, where connections are formed, knowledge is shared, and the latest advancements are unveiled. This exceptional platform brings together renowned speakers from across the globe, ensuring a mesmeric exchange of valuable experiences, profound insights, and exceptional expertise.

By participating in ISCO, you will seize the opportunity to enrich your clinical practice through transformative discussions, cutting-edge information, and collaborative engagements with your peers. As you gain inspiration and expand your knowledge, we believe that the outcomes for your patients will be significantly enhanced.

Get ready to embark on a journey of discovery, innovation, and personal growth at the ISCO congress where excellence in oncology meets limitless possibilities. At the heart of the upcoming ISCO 2025 Oncology Congress lies the transformative concept of Personomics – a personalized approach to cancer care that embraces individual uniqueness and complexities.

Join us in our interactive sessions and insightful discussions as we navigate through this innovative paradigm shift, guiding healthcare professionals towards tailored treatment strategies and patient-centered care. The Personomic Compass will illuminate new paths in oncology, fostering a deeper understanding of each individual's journey through the lens of precision medicine. Don't miss this opportunity to be a part of shaping the future of cancer care at the ISCO groundbreaking congress







Mohamed Yassin

Asst. Professor of Clinical Oncology

Ain Shams University



Tamer El Nahas

Professor of Clinical Oncology
Cairo University



Walid Arafaat
Professor of Clinical Oncology
Alexandria University





Emad Barsoum

MSc Oncology, Newcastle University, UK



Arranged Alphabetically



Axel Le Cesne

Head of the Institute`s International Department.
Former Head of the Sarcoma Committee at
Gustave Roussy Institute, France.
Co-chair of the French Sarcoma Group.
Former Member of the Board of Directors of the
Connective Tissue Oncology Society.



Fabrice André

President of European Society for Medical Oncology (ESMO) Director of Research, Gustave Roussy, France.



Karim Fizazi

Head of Urologic Pathology Committee, Gustave Roussy Institute, France Head of International Academic Network, Gustave Roussy Institute, France



Lobna Ezz El Arab

Prof, Clinical Oncology
Ex Head of oncology department
Ain Shams University
Egypt







Axel Le Cesne

Head of the Institute`s International Department.
Former Head of the Sarcoma Committee at
Gustave Roussy Institute, France.
Co-chair of the French Sarcoma Group.
Former Member of the Board of Directors of the
Connective Tissue Oncology Society.



Fabrice André

President of European Society for Medical Oncology (ESMO) Director of Research, Gustave Roussy, France.



Karim Fizazi

Head of Urologic Pathology Committee, Gustave Roussy Institute, France Head of International Academic Network, Gustave Roussy Institute, France



Thierry Le Chevalier

Former Head, Department of Medicine, Former Chief of Service, Medical Oncology, Former Chairman, Clinical Trials Committee Gustave-Roussy Institute, France



Arranged Alphabetically



Mohamed Abdallah

Head of Clinical Oncology Department, Cairo University. Professor of Clincal Oncology, Cairo University.



Mohamed Kilany

Ass. Professor of Clinical Oncology Faculty of Medicine, Ain Shams University



Mohsen Mokhtar

Professor of Clincal Oncology, Cairo University.



Raafat Abdelfattah

Professor of Oncology and
Hematology
Former Director of the National
Cancer Institute Hospitals, Cairo
University.



Strategic Planning & Managing Partner



Shereen El Saadawy

Founder & CEO
Cavallo D'Oro - Perfect Touch Events

Managing Director



Omneya Mansour

Master of Business Administration- Edinburgh Business School, UK



Arranged Alphabetically



Aalaa Gamil Ibrahim Lecturer of Clinical Oncology, Helwan University



Abdallah Khalil
Clinical Oncology Specialist and
Researcher M.D. in Clinical Oncology



Samy Samir
Clinical Oncology Advisor, Insurance
Industry.



Sayed Raafat

Assistant Lecturer of Medical Oncology,
Al-Azhar University



Suhad Meidan
cal Oncoloaist and Coord

Clinical Oncologist and Coordinator of Presidential Women's Health Initiative (PWHI) - Ministry of Health.





Alessandra Gennari



Alexandra Leary



Alina Danu



Antonio Llombart



Antonio Passaro



Axel Le Cesne



Dario Callegaro



David Planchard



Elizabeth Smyth



International Speakers



Fabrice André



Fabrice Barlesi



Hamdy Abdelazim



Jean Henri Bourhis



Juan Sepulveda



Julien Taieb



Karim Fizazi



Krishna B. Clough



Laurance Albiges





Loïc Renaud



Lori Bateman



Marc Peeters



Marc Spielmann



Mohamed Shelan



Mona Fouad



Nicoleta Colombo



Olaf Mercier



Paolo Tarantino



International Speakers



Patricia Pautier



Patrice Carde



Samuel Murray



Stéphane De Botton



Stefan Machtens



Thierry André



Thierry Le Chevalier



Yohann Loriot



09:00 12:00







GI cancers MSI/dMMR: immunotherapy hot topics in 2025 Thierry André

Management of metastatic Gastric/GEJ adenocarcinoma in 2025-where are we now?



Elizabeth Smyth



Last update on molecular treatment option for MSS mCRC with specific molecular alteration (HER2, KRAS G12C, BRAF, High TIL infiltrates)

Julien El Taieb

Anti-EGFR Therapy in mCRC: How to Incorporate into Practice and Manage Toxicities

Marc Peeters



12:00 13:00







Dr. Khaled Abdel Ghafar Minister of Health



Dr. Ayman Ashour
Minister of Higher Education



Dr. Eric Chevallier
French Ambassador



Prof. Axel Le Cesne Honorary President



Prof. Fabrice Andre
Honorary President

14:00 18:00







IO Advances upfront treatment in Metastatic NSCLC without molecular driven mutation.

Fabrice Barlesi



Antonio Passaro





Unresectable Stage III NSCLC: Patient Selection and Treatment Options

David Planchard

Current treatment landscape in SCLC

Thierry Le Chevalier





Lung cancer surgery: current and future strategies Olaf Mercier

MDT: Case discussion

18:00 19:00







Impact of surgery at specialized sarcoma centers on patients' outcome

Dario Callegaro

Summary of highlights of important trials in STS













Evolving therapeutic landscape of ADC in breast cancer

Hamdy Abd El Azim

Precision medicine in low grade gliomas. Shaping the future of neuro oncology.



Juan Sepulveda





Year of review: Precision medicine

Samuel Murray





Abstracts Oral Presentations

21:00 - 22:00




ISCO Exam



Faculty Dinner

23:00





09:00 12:00







2025 review: key updates in Hodgkin lymphoma Loïc Renaud

Update on treatment landscape in CML.







Update on treatment landscape in CLL.

Patrice Carde

Place of Auto/Allo BMT in lymphoid neoplasm in 2025

Jean Henri Bourhis












Stem cell transplantation In Egypt:35 years of experience

GamalEldin Fathi



AlinaDanu







12:20 15:40







updated landscape of adjuvant treatment for luminal breast cancer

Fabrice Andre

Key challenges in managing patients with HR+/ HER2- Metastatic Breast Cancer.







Covering the evolution of endocrine therapies, tackling mechanisms of resistance (AKT,ESR), and finally ADCs role in this space

Antonio Llombart

Early TNBC BRCA-mutant (Case discussion)

Marc Spielmann





Optimizing treatment sequence in metastatic TNBC

Paolo Tarantino

Immediate breast reconstruction by prothesis: Retro or pre-pectoral

Krishna Clough











Choosing medical treatment wisely in advanced uterine cancers.

Alexandra Leary









Long term outcomes of PARPi in ovarian cancers, OS and post progression insights

Nicoleta Colombo

18:00 21:00







1L Treatment Approaches in advanced RCC Laurance Albiges

Current and future options for metastatic castration-resistant prostate cancer after intensified treatment in the hormonesensitive setting







What might be the near future in non metastatic bladder cancer

Yohann Loriot

Role of SBRT in prostate cancer

Mohamed Shelan











Recent updates in management of mHSPC

(Aranote trial) Karim Fizazi

Role of PARPi in management of mCRPC (Talapro-2 trial)







Elevate your outcomes choose the best in mHSPC

Stefan Machtens

janssen

ISCO Exam





DINIER



Address:

Cairo - Egypt

18 Nabil Al Wakkad, Ard El Golf, Heliopolis, Cairo, Egypt

Istanbul - Turkey

Cumhuriyet Cd. Kolay #187-4, Harbiye Şişli, Istanbul, Turkey

Dubai - UAE

Saih Shuaib 2, Block J 05, Office 40 Dubai, UAE



Contact Us



+20 101 371 0330



+20 101 937 9836



+20 101 990 1117



+20 109 628 4040





info@pte-eg.com



pte-eg.com



P.O Box. 11769



perfect.touch.PTE

